The Trick Was Simple. The Damage Was Enormous.

Eli Lilly sells drugs to wholesalers, who then sell them to pharmacies. Federal law requires Lilly to report the Average Manufacturer Price (AMP) for every Medicaid-covered drug every quarter. The AMP directly determines how much Lilly owes back to the government as a rebate. Higher price reported: more money owed. Lower price reported: less money owed.

Starting in 2005, Lilly switched to a “fee-for-service” distribution model. Under this model, whenever Lilly raised a drug’s price after it had already shipped to a wholesaler but before the wholesaler resold it to a pharmacy, Lilly required the wholesaler to pay back the difference. The pharmacy still paid the higher price. Lilly still collected the higher price. But when Lilly calculated its AMP, it only reported the original, lower price it first charged the wholesaler.

In the court’s own words: Lilly sold a drug for $10, raised the price to $11, collected the full $11, and then told the government it only received $10. Multiplied across every Medicaid-covered drug, every quarter, for twelve years, that difference added up to $61.2 million in unpaid rebates owed to the American public.

The Math the Jury Saw

During the fraud period, Lilly generated over $600 million (more than the median American household earns in roughly 9,000 years of combined labor) in revenue from the exact price increases it excluded from its government reports. Internal company presentations tracked these clawback revenues for senior leadership. The clawbacks often approached $100 million per year. Lilly knew precisely what it was collecting. It chose not to tell the government.

Medicaid pays pharmacies the “usual and customary” price for brand-name drugs. That price went up every time Lilly raised its prices. So the government’s costs increased while Lilly’s reported obligation artificially stayed low. The system was designed so those two numbers would track each other. Lilly broke that link for profit.

The Non-Financial Ledger: What This Actually Cost Real People

The court documents count dollars. This section counts something the spreadsheets don’t. When Eli Lilly gamed Medicaid’s rebate formula, it was not stealing from an abstraction called “the government.” It was draining a program that exists for one reason: to make sure low-income Americans, elderly Americans, and disabled Americans can afford medicine. Every dollar Lilly withheld was a dollar that could not be allocated to expand coverage, reduce cost-sharing for beneficiaries, or help states fund other critical services for the same population.

Medicaid was created in 1965 because Congress recognized that market forces alone would leave poor and working-class Americans without access to healthcare. The Medicaid Drug Rebate Program was added in 1990 because, by the late 1980s, rising drug prices were already threatening the entire program’s ability to “simultaneously fund prescription drug and other health care needs of the elderly and the poor.” Eli Lilly signed onto that program in 1991. It agreed, in writing, to give the government a fair rebate in exchange for the guaranteed revenue stream of having its drugs covered by Medicaid. Then it spent the next fourteen years preparing to exploit a technicality that would let it take that revenue while minimizing what it gave back.

The human betrayal goes deeper than the balance sheet. The whistleblower who brought this case, Ronald Streck, first publicly accused pharmaceutical companies of this exact scheme in 2011. It took more than a decade of litigation, an entire jury trial, and a federal appeals court decision before Eli Lilly was held accountable. For most of that time, every Medicaid beneficiary who filled a prescription for one of Lilly’s drugs was, without knowing it, participating in a transaction where the company was quietly cheating the system that was supposed to protect them. The drugs got dispensed. The pharmacies got paid. Lilly got its revenue. And the rebate that was supposed to partially offset all of that cost stayed in Lilly’s pocket.

There is also a more intimate indignity buried in the court record. Heather Dixson was the mid-level government pricing specialist who made the decision to exclude the price increase values from AMP calculations. She was promoted into that role in 2005, the same month the new wholesaler contracts took effect. She could not recall discussing the decision with her predecessor, could not recall consulting supervisors, and Lilly produced zero documentation of her reasoning for the first six years of the scheme. Yet the executives above her, the ones who certified to the federal government that the AMP submissions were true and accurate, also admitted they had never read the contract they were certifying. One of the certifying executives, Frank Cunningham, admitted he did not recall ever reading the MDRP agreement and simply relied on Dixson. A company that generated hundreds of millions of dollars a year from these price increases assigned the accountability for their legality to a single mid-level employee with no documented guidance, and then had C-suite executives sign off on the results without looking at them. The jury saw that clearly.

Legal Receipts: In Their Own Words

The Court Calls Out the Scheme Directly

“Lilly increased prices, took more profit, but did not increase the AMP. It pocketed part of the rebate owed to the government.” — U.S. Court of Appeals, Seventh Circuit, September 11, 2025

The Court on Lilly’s “Good Faith Confusion” Defense

“Lilly’s exclusion of clawbacks from AMPs was not objectively reasonable since it contradicted the plain text of the law, regulations, and MDRP agreement, ran against the MDRP’s obvious purpose, and resulted in absurd consequences.” — U.S. Court of Appeals, Seventh Circuit, September 11, 2025

The 2011 Letter vs. the 2013 Audit: Two Very Different Tones

“Lilly’s explanation in the letter that it had every reason to think would go unreviewed was far more fulsome than its later response to the CMS audit that Lilly knew government officials would read.” — U.S. Court of Appeals, Seventh Circuit, September 11, 2025

The Footnote That Revealed the Cover-Up

“In contrast to the 2011 letter’s two-page description, Lilly incorporated an equivocal and partial explanation in a footnote: clawbacks were only excluded ‘if the underlying bona fide service fee test elements are satisfied.’ A reasonable factfinder could find this highly deceptive. Again, the clawbacks definitively did not satisfy the bona fide service fee test.” — U.S. Court of Appeals, Seventh Circuit, September 11, 2025

The Court on Lilly’s “Ostrich” Strategy

“Lilly’s stark turnabout in content and tone when it knew government officials were reading, versus when it knew they were not, is revelatory evidence of ‘ostrich-like’ conduct … where corporate officers insulate themselves from knowledge of false claims submitted by lower-level subordinates.” — U.S. Court of Appeals, Seventh Circuit, September 11, 2025 (quoting U.S. v. Sci. Applications Int’l Corp.)

The Court’s Warning About the System That Let This Happen

“We express our dismay at the government’s lethargy, or perhaps regulatory capture. The government allowed companies to make reasonable assumptions. The incentives to abuse this discretion are as clear as the opening bell on the New York Stock Exchange. Yet the government says it would not so much as review a letter. That policy runs the risk of rulemaking by regulatory prosecution. Moreover, the lack of industry-wide oversight likely cost taxpayers dearly.” — U.S. Court of Appeals, Seventh Circuit, September 11, 2025

Societal Impact Mapping

Public Health: The Program Built for Survival Was the Target

Medicaid is not a luxury program. It is the last financial firewall between millions of Americans and complete medical bankruptcy or preventable death. The court record is explicit: Congress created the Medicaid Drug Rebate Program in 1990 specifically because rising drug prices were threatening the program’s ability to fund “prescription drug and other health care needs of the elderly and the poor.” Eli Lilly exploited that same system for twelve years while its drugs remained covered by the program, meaning Medicaid beneficiaries continued receiving Lilly’s prescriptions, their states continued paying for them, and Lilly continued collecting full revenue while quietly pocketing the rebates it owed.

The mechanics of the fraud directly increased what the federal government paid out to pharmacies. Because Medicaid reimburses pharmacies for brand-name drugs based on the “usual and customary” price at the point of sale, and because Lilly’s price increases flowed directly to that price, every time Lilly raised a price, government costs went up. The rebate system was designed to offset that increase. Lilly refused to let it. The practical result: the program that serves the nation’s most medically vulnerable people paid more for Lilly’s drugs than it was supposed to, while Lilly paid less back than it was legally required to. The gap was $61.2 million (roughly what it costs to provide full Medicaid coverage to approximately 6,000 low-income adults for an entire year).

Economic Inequality: Who Benefits, Who Gets Robbed

Eli Lilly is one of the largest pharmaceutical companies in the world. During the fraud period alone, it collected over $600 million (more than what 12,000 median-wage American workers earn across their entire working lives) from the price increase mechanism it hid from the government. The people on the other end of that transfer were Medicaid beneficiaries: individuals and families who qualified for the program because they had little to no income. The wealth extracted from the public health program of last resort went directly into the revenue column of a corporation whose executives were tracked attending meetings where those same clawback figures were presented on slides to senior leadership.

The court confirmed that Lilly’s accounting maneuver was not the product of confusion or regulatory complexity. The law was clear. The contract Lilly signed in 1991 was clear. The 2007 federal regulation was clear. The 2010 Affordable Care Act amendment was clear. Lilly chose to interpret all of it in the most financially self-serving way possible, documented nothing for six years, assigned responsibility to a mid-level employee, had C-suite executives certify the accuracy of figures they admitted they never investigated, and collected hundreds of millions of dollars while the poorest Americans and their state governments absorbed the cost. The jury verdict of $183.7 million (enough to fund a small city’s entire public health department for a decade) was the law doing what it was designed to do. The question left unanswered by the court record is how many other drug companies ran the same play and never got caught.

The “Cost of a Life” Metric

What Now?

Corporate Roles of Interest

• Lilly’s Government Pricing Specialist (2005 onward): Heather Dixson. Managed AMP calculations for the entire fraud period with no documented oversight and no documented justification for the clawback exclusion.
• AMP Certifying Executive: Frank Cunningham. Signed off on AMP submissions as true and accurate to the federal government; admitted he never read the MDRP agreement he was certifying compliance with.
• Other Certifying Executives: [REDACTED – Not in Source]. CMS required that Lilly’s CEO, CFO, or their direct reports certify AMP accuracy. The source does not identify all certifiers by name beyond Cunningham.

The Court’s Own Warning About the Bigger Problem

The Seventh Circuit did not just rule against Eli Lilly. It fired a warning shot at the entire system. The court stated plainly that the government’s policy of refusing to even review letters from drug manufacturers about their AMP assumptions “runs the risk of rulemaking by regulatory prosecution” and that the lack of industry-wide oversight “likely cost taxpayers dearly.” This was not an isolated scheme. The whistleblower Ronald Streck originally sued fourteen other drug manufacturers for the same type of AMP manipulation. Lilly was just the one a jury got to decide.

What you can do right now: Contact your congressional representatives and demand that the HHS Office of Inspector General conduct a full industry-wide audit of Average Manufacturer Price reporting by every drug company participating in Medicaid. Demand that CMS reinstate a policy of actually reviewing AMP assumption letters from manufacturers. Support organizations that fund pharmaceutical pricing transparency research and Medicaid advocacy, including the National Health Law Program, Families USA, and your state’s Medicaid advocacy coalition. If you work inside a pharmaceutical company and know of similar reporting practices, the False Claims Act protects and financially rewards whistleblowers.